Searle NSAID-induced ulcer risk consumer awareness campaign kicks off.
This article was originally published in The Tan Sheet
Executive Summary
SEARLE NSAID GASTRIC ULCER RISK CONSUMER AWARENESS CAMPAIGN was unveiled March 19 in conjunction with the American Gastro- enterological Association. REDUCE, the Risk Education to Decrease Ulcer Complications and their Effects from NSAIDs, aims to increase public awareness of the "incidence of stomach ulcers and other serious gastrointestinal (GI) complications caused by common prescription and over-the-counter pain relievers known as non-steroidal anti-inflammatory drugs (NSAIDs)," Searle said. The company markets the Rx drug Arthrotec (diclofenac 50 or 75 mg/misoprostol 200 mcg) for pain relief and treatment of NSAID-induced ulcers.